1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Roopa Industries Limited

Roopa Industries Limited

BBSE:ROOPAIND
45.85
INR
+1.95
(+4.44%)
0.16EPS
310.74P/E
399.96MMarket Cap
Roopa Industries Limited
BSE:ROOPAIND
(Bombay Stock Exchange)

Recent

price

45.85

P/E

ratio

310.74

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
47.25
45.96
40.88
36.3
39.38
38.91
38.07
23.32
37.76
34.22
36.16
65.1
96.84
89.54
153.44
162.11
160.65
Revenue per Share
0.72
0.88
0.22
-2.55
0.2
0.22
0.24
0.69
0.77
0.47
0.91
1.29
1.72
1.93
2.59
0.11
0.16
Basic EPS, GAAP
0.75
0.04
-2.11
0.48
0.56
1.62
-1.95
-8.84
2.21
2.47
-1.6
1.91
-2.21
1.55
-9.47
5.25
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12.73
13.36
13.35
10.79
11
11.52
11.9
12.48
13.25
13.73
14.7
16
17.73
19.67
22.24
22.37
- -
Book Value per Share
12.73
13.36
13.35
10.79
11
11.52
11.9
12.48
13.25
13.73
14.7
16
17.73
19.67
22.24
22.37
- -
Tangible Book Value per Share
7
7
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
Basic Weighted Avg Shares
319
326
321
286
310
306
299
183
297
269
284
512
762
704
1,207
1,275
1,258
Sales/Revenue/Turnover
3.66
6.08
3.36
-2.71
5.17
5.33
7.85
-17.18
6.72
7.46
7.04
5.3
4.39
5.22
2.73
5.94
5.95
Operating Margin (%)
4
5
6
6
7
5
5
5
6
8
8
9
9
9
9
8
8
Depreciation Expense
5
6
2
-20
2
2
2
5
6
4
7
10
13
15
20
1
1
Net Income, GAAP
24.9
29.23
42.05
- -
8.93
35.15
55.92
- -
23.49
53.5
23.2
25.38
25.31
30.12
25.23
50.89
46.4
Effective Tax Rate (%)
1.52
1.91
0.55
-7.03
0.52
0.56
0.63
2.94
2.03
1.38
2.52
1.98
1.77
2.16
1.69
0.07
0.1
Profit Margin (%)
75
39
39
17
34
65
101
117
97
86
99
73
29
61
165
128
- -
Working Capital
55
28
24
27
34
49
70
101
95
74
78
41
20
53
64
21
- -
LT Debt
90
100
105
85
87
91
94
98
104
108
116
126
139
155
175
176
- -
Total Equity
3.46
4.25
1.12
- -
0.98
1.01
1.05
- -
6.13
3.85
6
7.63
8.58
7.03
5.32
3.16
- -
Return on Invested Capital (%)
3.46
4.25
1.12
- -
4.52
4.25
3.53
- -
5.52
3.4
5.67
7.14
8.25
8.08
8.31
2.94
- -
Return on Capital (%)
5.72
6.57
1.71
-21.14
1.88
1.94
2.04
5.63
5.97
3.51
6.41
8.41
10.17
10.33
12.34
0.47
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
286
- -
LT Borrowings
- -
21
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
346
308
400

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
632
- -
Cash, Cash Equivalents & STI
- -
15
- -
Accounts Receivable, Net
- -
219
- -
Inventories
- -
308
- -
Total Current Liabilities
- -
504
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
286
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.93%
8.85%
0.58%
Free Cash Flow
-161.7%
-294.27%
-155.43%
Net Income, GAAP
28.8%
5.06%
-95.92%
Sales/Revenue/Turnover
21.56%
39.66%
5.65%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
345
256
307
298
1,207
2026
351
287
335
301
1,275
2027
333
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.35
0.74
0.97
0.51
2.59
2026
0.36
0.59
0.98
-1.8
0.11
2027
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Roopa Industries Limited manufactures and markets active pharmaceutical ingredients, pharmaceutical intermediates, nutraceuticals, bulk drugs, and fine chemicals in India and internationally; core products include triphenyl phosphine for cephalosporin antibiotics, statins, specialty resins, paints, fire retardants, phosphonium salts, phase transfer catalysts, and agricultural applications; glucosamine as a nutritional supplement for arthritis treatment; bromine and its derivatives such as meta bromo anisole, tetra butyl ammonium bromide, 1-bromo-3-chloropropane, and 1-acetoxy ethyl bromide for agro chemicals, dyes, organic and inorganic intermediates, medical and veterinary products, gasoline applications, water purification, disinfectants, insecticides, pesticides, and mercury decontamination; N,N-dicyclohexylcarbodiimide; and 5-cyano phthalide. The company, founded in 1985 and headquartered in Hyderabad, India, with manufacturing facilities in Patancheru and Adoni in Andhra Pradesh, employs over 150 qualified staff including a research and development division and serves global customers with customized requirements through world-class infrastructure. Roopa Industries maintains operations in the chemicals and pharmaceuticals sectors targeting pharmaceutical manufacturers, nutraceutical producers, and industrial chemical users; it recently experienced a fire incident in a storage room for raw materials, work-in-progress, and finished goods at its Patancheru plant on November 3, 2025.